{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:41:11Z","timestamp":1790314871455,"version":"4.1.0"},"reference-count":30,"publisher":"The Endocrine Society","issue":"8","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Most of the patients included in the clinical trials and real-world studies with osilodrostat only include patients with adrenocorticotropic hormone dependent Cushing syndrome (CS), while data on the efficacy and safety of osilodrostat in patients with adrenal CS is scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the efficacy and safety of osilodrostat in adrenal CS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>International study of patients with adrenal CS: patients treated with osilodrostat at any time were enrolled in the safety evaluation and those treated for longer than 4 weeks, in the efficacy evaluation. Patients were classified as responders if they experienced a reduction in urinary free cortisol (UFC) &amp;gt;50% (complete responders when UFC levels were below the upper limit of normal [ULN] and partial responders if there was a reduction &amp;gt;50% but not normalization).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-eight patients with adrenal CS were enrolled: 16 with adrenocortical carcinoma and 12 with benign disease. Osilodrostat was used in monotherapy in 22 patients and in combination with metyrapone in 6 cases. In those patients treated for longer than 4 weeks (n = 21), 66.7% were classified as responders (28.6% with complete response and 38.1% with partial response), and for those treated for longer than 12 weeks, the rate of response increased to 87.5% The use of osilodrostat as a nonfirst-line therapy (odds ratio 15.0, P = .010) was a predictor of response. Osilodrostat led to a significant decrease in systolic blood pressure and body weight (P &amp;lt; .05). Nine patients developed one or more adverse events and in 56% (n = 5) led to osilodrostat discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Osilodrostat controls hypercortisolism in 66.7% of patients with adrenal CS treated for longer than 4 weeks and in 87.5% of cases treated for longer than 12 weeks, with a positive impact on blood pressure and body weight. Patients who received osilodrostat after other previous steroidogenesis inhibitors have a higher probability of response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag115","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:47:08Z","timestamp":1773330428000},"page":"2180-2189","source":"Crossref","is-referenced-by-count":1,"title":["International real-world study on osilodrostat efficacy and safety in adrenal Cushing syndrome"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0519-0072","authenticated-orcid":false,"given":"Marta","family":"Araujo-Castro","sequence":"first","affiliation":[{"name":"Endocrinology and Nutrition Department, Hospital Universitario Ram\u00f3n y Cajal , Madrid 28034 ,","place":["Spain"]},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica Ram\u00f3n y Cajal (IRYCIS) , Madrid 28034 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9332-2524","authenticated-orcid":false,"given":"Irina","family":"Bancos","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Nutrition, Mayo Clinic , Rochester, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1490-5575","authenticated-orcid":false,"given":"Mario","family":"Detomas","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of W\u00fcrzburg , W\u00fcrzburg 97080 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9817-9875","authenticated-orcid":false,"given":"Martin","family":"Reincke","sequence":"additional","affiliation":[{"name":"Department of Medicine IV, LMU University Hospital, LMU Munich , Munich 81377 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Salehi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Nutrition, Mayo Clinic , Rochester, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Lu","sequence":"additional","affiliation":[{"name":"Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Key Laboratory of Hereditary Rare Diseases of Health Commission of Henan Province, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology , Luoyang 471003 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2616-3249","authenticated-orcid":false,"given":"Barbara","family":"Altieri","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of W\u00fcrzburg , W\u00fcrzburg 97080 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Kroiss","sequence":"additional","affiliation":[{"name":"Department of Medicine IV, LMU University Hospital, LMU Munich , Munich 81377 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Oettle","sequence":"additional","affiliation":[{"name":"Department of Medicine IV, LMU University Hospital, LMU Munich , Munich 81377 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Guerrero-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Bellvitge University Hospital-IDIBELL , L\u2019Hospitalet de Llobregat, Barcelona 08907 ,","place":["Spain"]},{"name":"Biomedical Research Institute of Bellvitge (IDIBELL) , L\u2032Hospitalet de Llobregat, Barcelona 08907 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia A","family":"Hanzu","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Department and Institut de Investigacions Biomediques Pi I Sunyer Barcelona, Hospital Cl\u00ednic of Barcelona, University Barcelona , Barcelona 08036 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogelio","family":"Garc\u00eda-Centeno","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Department, Hospital Universitario Gregorio Mara\u00f1\u00f3n , Madrid 28007 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"G\u00f3nzalez-Fernandez","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Department, Hospital Universitario Gregorio Mara\u00f1\u00f3n , Madrid 28007 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Pasar\u00f3n","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Department, Hospital Universitario de Cabue\u00f1es , Gij\u00f3n (Asturias) 33203 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Gracia Gimeno","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Department, Hospital Universitario Royo Villanova , Zaragoza 50015 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Manzano Valero","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Department, Hospital Universitario Toledo , Toledo 45007 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Castro Luna","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Department, Hospital Universitario Toledo , Toledo 45007 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Irigaray Echarri","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Department, Hospital Universitario Navarra , Pamplona 31008 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Dolores","family":"Ollero Garcia-Argullo","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Department, Hospital Universitario Navarra , Pamplona 31008 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6079-6974","authenticated-orcid":false,"given":"Wilfredo Antonio","family":"Rivera Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Cl\u00ednica Imbanaco , Cali 760042 ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"issue":"7","key":"2026071419581347700_dgag115-B1","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","article-title":"Complications of Cushing's syndrome: state of the art","volume":"4","author":"Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2026071419581347700_dgag115-B2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41572-024-00588-w","article-title":"Cushing syndrome","volume":"11","author":"Nieman","year":"2025","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"2026071419581347700_dgag115-B3","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1093\/ejendo\/lvad066","article-title":"European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"189","author":"Fassnacht","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026071419581347700_dgag115-B4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ecl.2018.02.003","article-title":"Adrenocortical carcinoma with hypercortisolism","volume":"47","author":"Puglisi","year":"2018","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"6","key":"2026071419581347700_dgag115-B5","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s11154-025-09989-y","article-title":"Management of Cushing's syndrome in patients with adrenocortical cancer: state of the art and future perspectives","volume":"26","author":"Guarnotta","year":"2025","journal-title":"Rev Endocr Metab Disord"},{"issue":"10","key":"2026071419581347700_dgag115-B6","doi-asserted-by":"crossref","first-page":"501654","DOI":"10.1016\/j.endinu.2025.501654","article-title":"Executive summary of the consensus document for the management of severe Cushing's syndrome: consensus document of the Neuroendocrinology Focus Group of the Spanish Society of Endocrinology and Nutrition (SEEN)","volume":"72","author":"Araujo-Castro","year":"2025","journal-title":"Endocrinol Diabetes y Nutr"},{"issue":"6","key":"2026071419581347700_dgag115-B7","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1210\/clinem\/dgac691","article-title":"Efficacy and safety of osilodrostat in paraneoplastic Cushing syndrome: a real-world multicenter study in France","volume":"108","author":"Dormoy","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026071419581347700_dgag115-B8","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11102-015-0692-z","article-title":"Osilodrostat, a potent oral 11\u03b2-hydroxylase inhibitor: 22-week, prospective, phase II study in Cushing's disease","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"issue":"9","key":"2026071419581347700_dgag115-B9","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","article-title":"Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase","volume":"8","author":"Pivonello","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"2026071419581347700_dgag115-B10","doi-asserted-by":"crossref","first-page":"E2882","DOI":"10.1210\/clinem\/dgac178","article-title":"Randomized trial of osilodrostat for the treatment of Cushing disease","volume":"107","author":"Gadelha","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026071419581347700_dgag115-B11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1530\/EJE-22-0317","article-title":"Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension","volume":"187","author":"Fleseriu","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"2026071419581347700_dgag115-B12","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1530\/EJE-21-1008","article-title":"Efficacy and tolerance of osilodrostat in patients with Cushing's syndrome due to adrenocortical carcinomas","volume":"186","author":"Tabarin","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"21","key":"2026071419581347700_dgag115-B13","doi-asserted-by":"crossref","first-page":"7575","DOI":"10.3390\/jcm14217575","article-title":"Real-world data on the efficacy and safety of osilodrostat in patients with Cushing's disease in Spain","volume":"14","author":"Araujo-Castro","year":"2025","journal-title":"J Clin Med"},{"issue":"6","key":"2026071419581347700_dgag115-B14","doi-asserted-by":"crossref","first-page":"674","DOI":"10.5603\/ep.106857","article-title":"Successful non-surgical treatment of bilateral macronodular adrenocortical disease with osilodrostat","volume":"76","author":"Laskowski","year":"2025","journal-title":"Endokrynol Pol"},{"issue":"6","key":"2026071419581347700_dgag115-B15","doi-asserted-by":"crossref","first-page":"luaf091","DOI":"10.1210\/jcemcr\/luaf091","article-title":"Prolonged adrenal insufficiency after failed cryoablation and osilodrostat for Cushing syndrome in nodular adrenal disease","volume":"3","author":"Veloski","year":"2025","journal-title":"JCEM Case Rep"},{"key":"2026071419581347700_dgag115-B16","doi-asserted-by":"crossref","first-page":"bvaf046","DOI":"10.1210\/jendso\/bvaf046","article-title":"Osilodrostat treatment of Cushing syndrome in real-world clinical practice: findings from the ILLUSTRATE study","volume":"9","author":"Fleseriu","year":"2025","journal-title":"J Endocr Soc"},{"issue":"(5)","key":"2026071419581347700_dgag115-B17","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1210\/clinem\/dgaf633","article-title":"Real-world osilodrostat effectiveness and safety in nonpituitary Cushing syndrome","volume":"111","author":"Tabarin","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071419581347700_dgag115-B18","first-page":"3141","article-title":"Cushing syndrome","volume":"11","author":"Motohashi","year":"2025","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"2026071419581347700_dgag115-B19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/cncr.24030","article-title":"Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification","volume":"115","author":"Fassnacht","year":"2009","journal-title":"Cancer"},{"key":"2026071419581347700_dgag115-B20","author":"Araujo-Castro"},{"key":"2026071419581347700_dgag115-B21","doi-asserted-by":"crossref","first-page":"1236465","DOI":"10.3389\/fendo.2023.1236465","article-title":"Long-term efficacy and safety of osilodrostat in patients with Cushing's disease: results from the LINC 4 study extension","volume":"14","author":"Gadelha","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"2026071419581347700_dgag115-B22","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2013-3628","article-title":"Ketoconazole in Cushing's disease: is it worth a try","volume":"99","author":"Castinetti","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026071419581347700_dgag115-B23","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s11102-018-0897-z","article-title":"Effectiveness of medical treatment for Cushing's syndrome: a systematic review and meta-analysis","volume":"21","author":"Broersen","year":"2018","journal-title":"Pituitary"},{"issue":"12","key":"2026071419581347700_dgag115-B24","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.3390\/biomedicines11123227","article-title":"Cushing's disease: long-term effectiveness and safety of osilodrostat in a polish group of patients with persistent hypercortisolemia in the experience of a single center","volume":"11","author":"Dzialach","year":"2023","journal-title":"Biomedicines"},{"key":"2026071419581347700_dgag115-B25","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-025-02769-0","article-title":"Efficacy and safety of osilodrostat in patients with ectopic Cushing\u2019s syndrome. a real-world study in Spain","author":"Araujo-Castro","year":"2025","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"2026071419581347700_dgag115-B26","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1530\/EJE-13-0519","article-title":"Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center","volume":"169","author":"Ayala-Ramirez","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2026071419581347700_dgag115-B27","doi-asserted-by":"crossref","first-page":"506\u2013","DOI":"10.1093\/ejendo\/lvaf207","article-title":"Osilodrostat dose impact on efficacy\/safety in Cushing's disease: large, pooled analysis of LINC 2, 3, and 4","volume":"193","author":"Fleseriu","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026071419581347700_dgag115-B28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11102-024-01471-3","article-title":"Osilodrostat improves blood pressure and glycemic control in patients with Cushing's disease: a pooled analysis of LINC 3 and LINC 4 studies","volume":"28","author":"Fleseriu","year":"2025","journal-title":"Pituitary"},{"issue":"3","key":"2026071419581347700_dgag115-B29","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4103\/ijem.ijem_260_23","article-title":"Efficacy and safety of osilodrostat in managing Cushing's syndrome: a systematic review and meta-analysis","volume":"28","author":"Nagendra","year":"2024","journal-title":"Indian J Endocrinol Metab"},{"issue":"12","key":"2026071419581347700_dgag115-B30","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1210\/clinem\/dgaf206","article-title":"Chronotherapy with once-daily osilodrostat improves cortisol rhythm, quality of life, and sleep in Cushing's syndrome","volume":"110","author":"Ferrari","year":"2025","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag115\/67342090\/dgag115.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/8\/2180\/67342090\/dgag115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/8\/2180\/67342090\/dgag115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:58:40Z","timestamp":1784073520000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/8\/2180\/8519556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,3,13]]},"published-print":{"date-parts":[[2026,7,15]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag115","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,3,13]]}}}